Global Pharmaceutical CDMO Market projected to hit $270.3 billion by 2031 driven by a 7.2% CAGR
Executive summary: A new report by Wissen Research forecasts that the global pharmaceutical CDMO market will grow at a CAGR of 7.2% between 2026 and 2031, reaching a total valuation of $270.3 billion. The projected growth underscores the critical role of third-party manufacturers in the global drug supply chain and the increasing reliance of biotech and pharma firms on outsourced expertise.
Who is involved: Wissen Research (reporting entity), global pharmaceutical companies, and CDMO service providers.
Likely next: Increased capital expenditure by CDMO players to expand manufacturing facilities and capacity to meet long-term demand.
The pharmaceutical contract development and manufacturing organization (CDMO) market is forecast to expand from roughly $191 billion in 2026 to $270.3 billion by 2031, reflecting a compound annual growth rate of 7.2 %. This trajectory underscores a broader shift in drug‑development strategies, whereby sponsors increasingly delegate complex synthesis, formulation and scale‑up tasks to specialized external partners. The growth is reinforced by robust demand in niche segments such as oligonucleotide therapeutics, which are projected to reach $11.14 billion by the same year, indicating that advanced modalities are a significant contributor to overall CDMO activity. For industry participants, the sustained expansion translates into heightened capital commitments for manufacturing capacity, technology upgrades and workforce expertise. Recent commentary from Viva Biotech highlights how artificial‑intelligence tools are beginning to reshape R&D workflows and accelerate commercial‑manufacturing output, suggesting that CDMOs that integrate AI‑driven process optimization may capture a larger share of the incremental revenue. In the near term, we can expect continued investment in Asian hubs, further consolidation among mid‑size players, and a steady rise in outsourced volumes as drug pipelines grow more complex.
What's next — scenarios
Base Case: Steady expansion (65%)
CDMOs continue to grow at the projected 7.2% CAGR, focusing on standard biologics and small molecules.
- Stable drug approval rates by FDA/EMA
- Consistent outsourcing trends among mid-cap biotech firms
Upside: Specialized tech acceleration (25%)
Growth exceeds 7.2% as demand for complex modalities like oligonucleotides and cell therapies surges.
- Breakthroughs in mRNA or gene therapy commercialization
- Rapid adoption of AI in drug manufacturing processes
Downside: Supply chain protectionism (10%)
Growth slows below 7.2% due to geopolitical shifts forcing companies to reshore manufacturing.
- New trade restrictions on pharmaceutical intermediates
- Nationalistic drug manufacturing policies in major economies
What to watch
- Annual revenue growth reports from major CDMO players
- New facility announcements and capacity expansions in the sector
- Regulatory shifts regarding drug manufacturing outsourcing
Timeline
- — Pharmaceutical CDMO Market to Reach US$ 270.3 Bn by 2031, Growing at 7.2% CAGR, New Report by Wissen Research (PR Newswire)
- — Oligonucleotide CDMO Market worth $11.14 billion by 2031 - Exclusive Report by MarketsandMarkets™ (PR Newswire)
Analysis — what this means
Likely next events
- Observation of 2027 budget allocations for in-house vs outsourced legal and manufacturing services
Sectors affected
- Biotechnology
- Pharmaceutical manufacturing
- Life sciences laboratory equipment
- Specialized chemical supply
Regulatory implications
- Increased scrutiny on global supply chain integrity by health authorities
- Compliance requirements for cGMP manufacturing standards in new facilities
Historical parallels
- Oligonucleotide CDMO market expansion (2026-2031 projection)
- Stem Cells market growth (2026-2031 projection)
Key entities
Sources
- Pharmaceutical CDMO Market to Reach US$ 270.3 Bn by 2031, Growing at 7.2% CAGR, New Report by Wissen Research — PR Newswire
- Oligonucleotide CDMO Market worth $11.14 billion by 2031 - Exclusive Report by MarketsandMarkets™ — PR Newswire
Related cases
- Viva Biotech’s 2026 interim results show AI‑driven drug R&D and CDMO manufacturing lifting revenue 21% year‑on‑year
- Southeast Asia's data center market is projected to attract $35.08 billion in cumulative investment by 2031, driven by a 14.3% CAGR
- Cut flower market projected to grow to $52.78 billion by 2031 as online ordering and cold‑chain advances reshape global trade
- The global trailer tire (ST-type) market is forecast to grow to USD 13.69 billion by 2035, driven by a 5.03% CAGR as freight transport demand expands
- DelveInsight forecasts the congestive heart failure market to expand at an 8% CAGR through 2036, signaling rising therapeutic and device demand amid an aging population
- The degenerative disc disease therapy market is forecast to expand at about a 19% CAGR to 2036 as regenerative drug candidates move toward clinical testing